The DOI matches its Crossref record; 200 of the 201 references it cites were found in a registry or an index.
Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Open accessAbstract
Amyloid-β proteins (Aβ) of 42 (Aβ42) and 40 aa (Aβ40) accumulate as senile plaques (SP) and cerebrovascular amyloid protein deposits that are defining diagnostic features of Alzheimer's disease (AD). A number of rare mutations linked to familial AD (FAD) on the Aβ precursor protein (APP), Presenilin-1 (PS1), Presenilin- 2 (PS2), Adamalysin10, and other genetic risk factors for sporadic AD such as the ε4 allele of Apolipoprotein E (ApoE-ε4) foster the accumulation of Aβ and also induce the entire spectrum of pathology associated with the disease. Aβ accumulation is therefore a key pathological event and a prime target for the prevention and treatment of AD. APP is sequentially processed by β-site APP cleaving enzyme (BACE1) and γ-secretase, a multisubunit PS1/PS2-containing integral membrane protease, to generate Aβ. Although Aβ accumulates in all forms of AD, the only pathways known to be affected in FAD increase Aβ production by APP gene duplication or via base substitutions on APP and γ-secretase subunits PS1 and PS2 that either specifically increase the yield of the longer Aβ42 or both Aβ40 and Aβ42. However, the vast majority of AD patients accumulate Aβ without these known mutations. This led to proposals that impairment of Aβ degradation or clearance may play a key role in AD pathogenesis. Several candidate enzymes, including Insulin-degrading enzyme (IDE), Neprilysin (NEP), Endothelin-converting enzyme (ECE), Angiotensin converting enzyme (ACE), Plasmin, and Matrix metalloproteinases (MMPs) have been identified and some have even been successfully evaluated in animal models. Several studies also have demonstrated the capacity of γ-secretase inhibitors to paradoxically increase the yield of Aβ and we have recently established that the mechanism is by skirting Aβ degradation. This review outlines major cellular pathways of Aβ degradation to provide a basis for future efforts to fully characterize the panel of pathways responsible for Aβ turnover.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cerebrospinal fluid (CSF) levels of the angiotensin-converting enzyme (ACE) are associated with Aβ levels81 and LOAD risk82, and studies show ACE can inhibit Aβ toxicity and aggregation83.”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [83]
In the citing paper
“In the hippocampus of AD patients, the enzymes IDE, ACE and NEP had decreased activity.30”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 2×
“tyl protease with an acid pH optimum, in an endosome where -secretase is also present and converts CTF to A [25, 45].”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., & Soubrier, F. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114844 · Cited by 3,767
Structure and function of matrix metalloproteinases and TIMPs
Nagase, H., Visse, R., & MURPHY, G. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.002 · Cited by 3,507
2013 Alzheimer's disease facts and figures
Thies, W. H., & Bleiler, L. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,372
Research works printed but not linked: 1
- [23]Sambamurti K Greig NH Utsuki T Barnwell EL Sharma E Mazell C Targets for AD treatment: conflicting messages from gamma-secretase inhibitors J Neurochem 117 3 359 74 2011 21320126 PMC3076515
Cited by
Sorted by citations
Items 101–200 of 332
Ettcheto, M., Sánchez‐López, E., Pons, L., Busquets, O., Olloquequi, J., Beas‐Zárate, C., Pallàs, M., García, M. L., Auladell, C., Folch, J., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.06.003 · Cited by 39
Chen, C., Ding, L., Fu, F., & Xiao, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14195 · Cited by 37
Comprehensive Overview of Alzheimer’s Disease: Etiological Insights and Degradation Strategies
Singh, M. K., Shin, Y., Ju, S., Han, S., Kim, S. S., & Kang, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136901 · Cited by 43
Ali, J., Choe, K., Park, J. S., Park, H. Y., Kang, H., Park, T. J., & Kim, M.-O. (2024) · Antioxidants · doi:10.3390/antiox13070862 · Cited by 42
Ntsapi, C., Lumkwana, D., Swart, C., du Toit, A., & Loos, B. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.002 · Cited by 39
(−)-Phenserine inhibits neuronal apoptosis following ischemia/reperfusion injury
Chang, C.-F., Lai, J.-H., Wu, J. C.-C., Greig, N. H., Becker, R. E., Luo, Y., Chen, Y., Kang, S.-J., Chiang, Y. H., & Chen, K. (2017) · Brain Research · doi:10.1016/j.brainres.2017.09.015 · Cited by 38
Self-citationQiao, H., Zhao, W., Guo, M., Zhu, L., Chen, T., Wang, J., Xu, X., Zhang, Z., Wu, Y., & Chen, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115981 · Cited by 43
Pharmacological Interventions to Attenuate Alzheimer’s Disease Progression: The Story So Far
Bazzari, F. H., Abdallah, D. M., & El-Abhar, H. S. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190301111120 · Cited by 39
Abu‐Elfotuh, K., Selim, H. M. R. M., Riad, O. K. M., Hamdan, A. M., Hassanin, S. O., Sharif, A. F., Moustafa, N. M., Gowifel, A. M. H., Mohamed, M. Y. A., Atwa, A. M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1208252 · Cited by 36
Krishnan, D., Menon, R. N., Mathuranath, P. S., & Gopala, S. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.02.001 · Cited by 36
van Weering, J. R. T., & Scheper, W. (2019) · CNS Drugs · doi:10.1007/s40263-019-00643-1 · Cited by 38
Zhu, Y., Ding, X., She, Z., Bai, X., Nie, Z., Wang, F., Wang, F., & Geng, X. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200810164932 · Cited by 36
Kunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Maiti, P., & Dunbar, G. L. (2017) · International Journal of Alzheimer s Disease · doi:10.1155/2017/4164872 · Cited by 34
iPSC model of CHRFAM7A effect on α7 nicotinic acetylcholine receptor function in the human context
Ihnatovych, I., Nayak, T. K., Ouf, A., Süle, N., Birkaya, B. G., Chaves, L. D., Auerbach, A. L., & Szigeti, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0375-z · Cited by 34
Martin, S., Lazzarini, M., Dullin, C., Balakrishnan, S., Gomes, F. V., Ninković, M., Hady, A. E., Pardo, L. A., Stühmer, W., & Bel, E. A. D. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9680-6 · Cited by 32
Thiosemicarbazone Derivatives as Inhibitors of Amyloid-β Aggregation: Effect of Metal Coordination
Matesanz, A. I., Caballero, A. B., Lorenzo, C., Espargaró, A., Sabaté, R., Quiroga, A. G., & Gámez, P. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c00467 · Cited by 32
García‐Viñuales, S., Sciacca, M. F. M., Lanza, V., Santoro, A. M., Grasso, G., Tundo, G. R., Sbardella, D., Coletta, M., Grasso, G., Rosa, C. L., et al. (2021) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2021.105072 · Cited by 34
Deep Learning Based Alzheimer Disease Diagnosis: A Comprehensive Review
Suganyadevi, S., Pershiya, A. S., Balasamy, K., Seethalakshmi, V., Bala, S., & Arora, K. (2024) · SN Computer Science · doi:10.1007/s42979-024-02743-2 · Cited by 31
An, X.-Q., Xi, W., Gu, C.-Y., & Huang, X. (2018) · médecine/sciences · doi:10.1051/medsci/201834f120 · Cited by 31
Sahoo, B. R., Bekier, M. E., Liu, Z., Kocman, V., Stoddard, A. K., Anantharamaiah, G. M., Nowick, J. S., Fierke, C. A., Wang, Y., & Ramamoorthy, A. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.12.005 · Cited by 30
Xiao, L., Liao, F., Ide, R., Horie, T., Fan, Y., Saiki, C., & Miwa, N. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.285000 · Cited by 31
Jeon, S. H., Kim, N., Ju, Y., Gee, M. S., Lee, D., & Lee, J. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228425 · Cited by 32
Alexandrov, P. N., Kruck, T. P. A., & Lukiw, W. J. (2015) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2015.07.013 · Cited by 29
Li, X., Song, J., & Dong, R. (2019) · Cytotechnology · doi:10.1007/s10616-019-00313-6 · Cited by 29
Rahman, M. A., Rahman, M. H., Mamun-Or-Rashid, A. N. M., Hwang, H., Chung, S., Kim, B., & Rhim, H. (2022) · Biomedicines · doi:10.3390/biomedicines10051027 · Cited by 31
Porphyrin Cyclodextrin Conjugates Modulate Amyloid Beta Peptide Aggregation and Cytotoxicity
Oliveri, V., Zimbone, S., Giuffrida, M. L., Bellia, F., Tomasello, M. F., & Vecchio, G. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201800807 · Cited by 29
Park, H. J., Jung, I. H., Kwon, H., Yu, J., Jo, E., Kim, H., Park, S. J., Lee, Y. C., Kim, D. H., & Ryu, J. H. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.12.043 · Cited by 30
Dendrobium alkaloids decrease Aβ by regulating α- and β-secretases in hippocampal neurons of SD rats
Huang, J., Huang, N., Zhang, M., Nie, J., Xu, Y., Wu, Q., & Shi, J. (2019) · PeerJ · doi:10.7717/peerj.7627 · Cited by 28
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28
Boeddrich, A., Haenig, C., Neuendorf, N., Blanc, E., Ivanov, A., Kirchner, M., Schleumann, P., Bayraktaroğlu, I., Richter, M., Molenda, C., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01206-2 · Cited by 30
The Microglial Response to Neurodegenerative Disease
Song, W. M., & Colonna, M. (2018) · Advances in immunology · doi:10.1016/bs.ai.2018.04.002 · Cited by 30
Bhowmick, D. C., & Jeremic, A. M. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002414 · Cited by 28
de la Monte, S. M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230555 · Cited by 28
Chen, J., Zhang, T., Jiao, S., Zhou, X., Zhong, J., Wang, Y., Liu, J., Deng, J., Wang, S., & Xu, Z. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161191 · Cited by 28
Kuo, Y., & Rajesh, R. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1621750 · Cited by 27
Liu, X., Wang, N., Jia, Y., Zhang, B., Xue, D., Reeju, M., Li, Y., & Huang, S.-M. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.205107 · Cited by 26
Antioxidant Modulation of mTOR and Sirtuin Pathways in Age-Related Neurodegenerative Diseases
Abdullah, A., Murshid, N. M., & Makpol, S. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02083-1 · Cited by 29
Saxena, S. K., Ansari, S., Maurya, V. K., Kumar, S., Sharma, D. K., Malhotra, H., Tiwari, S., Srivastava, C., Paweska, J. T., Abdel-Moneim, A. S., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00400 · Cited by 27
Endosomal traffic disorders: a driving force behind neurodegenerative diseases
Dong, J., Tong, W., Liu, M., Liu, M., Liu, J., Jin, X., Chen, J., Jia, H., Gao, M., Wei, M., et al. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00460-7 · Cited by 27
Wang, L., Liu, W., Fan, Y., Liu, T., & Yu, C. (2017) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2017.8669 · Cited by 24
Differential regulation of insulin signalling by monomeric and oligomeric amyloid beta-peptide
Molina-Fernández, R., Picón-Pagès, P., Barranco-Almohalla, A., Crepin, G., Herrera-Fernández, V., García-Elías, A., Fanlo-Ucar, H., Fernàndez‐Busquets, X., García‐Ojalvo, J., Oliva, B., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac243 · Cited by 23
Kim, H., Kim, S., Cho, B., Shin, J., & Kim, J. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00319-9 · Cited by 22
Comparison of Synthetic Neuronal Model Membrane Mimics in Amyloid Aggregation at Atomic Resolution
Bera, S., Gayen, N., Mohid, S. A., Bhattacharyya, D., Krishnamoorthy, J., Sarkar, D., Choi, J., Sahoo, N., Mandal, A. K., Lee, D., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00166 · Cited by 23
Protein structures in Alzheimer's disease: The basis for rationale therapeutic design
Montoliu‐Gaya, L., & Villegas, S. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.10.005 · Cited by 24
Begić, E., Hadžidedić, S., Kulaglić, A., Ramić-Brkić, B., Begić, Z., & Čaušević, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212261 · Cited by 22
Blood-Based Biomarkers of Alzheimers Disease: Diagnostic Algorithms and New Technologies
Carmona, P., Molina, M., & Tolédano, A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666151116130301 · Cited by 21
Target Enzymes Considered for the Treatment of Alzheimer’s Disease and Parkinson’s Disease
Kim, N., & Lee, H. J. (2020) · BioMed Research International · doi:10.1155/2020/2010728 · Cited by 22
Zhang, X., O’Callaghan, P., Li, H., Tan, Y.-X., Zhang, G., Barash, U., Wang, X., Lannfelt, L., Vlodavsky, I., Lindahl, U., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01182-x · Cited by 19
Lai, M. C., Liu, W. Y., Liou, S., & Liu, I.-M. (2022) · Nutrients · doi:10.3390/nu14112248 · Cited by 20
Simino, J. M., Wang, Z., Bressler, J., Chouraki, V. A., Yang, Q., Younkin, S. G., Seshadri, S. S., Fornage, M., Boerwinkle, E., & Mosley, T. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180046 · Cited by 20
Proust, A. M., Barat, C., Lebœuf, M., Drouin, J., Gagnon, M., Vanasse, F., & Tremblay, M. J. (2020) · Glia · doi:10.1002/glia.23833 · Cited by 19
Sorrentino, S., Ascari, R., Maderna, E., Catania, M., Ghetti, B. F., Tagliavini, F., Giaccone, G., & Fede, G. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052780 · Cited by 23
Tzekaki, E. E., Tsolaki, M., Pantazaki, Α. A., Geromichalos, G. D., Lazarou, E., Kozori, M., & Sinakos, Z. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111344 · Cited by 21
Cai, J., Yi, P., Miao, Y., Liu, J., Hu, Y., Liu, Q., Feng, Y., Chen, H., & Li, L. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c01597 · Cited by 19
Morey, T. M., Esmaeili, M. A., Duennwald, M. L., & Rylett, R. J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.722560 · Cited by 19
Calpain-Mediated Alterations in Astrocytes Before and During Amyloid Chaos in Alzheimer’s Disease
Schultz, B., Taday, J., Menezes, L., Cigerce, A., Leite, M. C., & Gonçalves, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215182 · Cited by 19
Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity
Forest, K. H., & Nichols, R. A. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.05.013 · Cited by 19
Tsay, H.-J., Liu, H., Kuo, Y., Chiu, C.-S., Liang, C.-C., Chung, C.-W., Chen, C., Chen, Y.-P., & Shiao, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910413 · Cited by 19
Hu, H., Wan, S., Hu, Y., Wang, Q., Li, H., & Zhang, N. (2025) · Annals of Medicine · doi:10.1080/07853890.2024.2445194 · Cited by 20
Electromagnetic radiation and Alzheimer’s disease
Dasdag, O., Adalier, N., & Daşdağ, S. (2020) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2020.1820378 · Cited by 18
An inorganic overview of natural Aβ fragments: Copper(II) and zinc(II)-mediated pathways
Lanza, V., Bellia, F., & Rizzarelli, E. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.04.004 · Cited by 18
Sun, H., Li, W., Zhu, C., Jin, W., Liu, Y.-H., Zeng, F., Wang, Y., & Bu, X. (2018) · BioMed Research International · doi:10.1155/2018/7302045 · Cited by 18
Cai, M., Jung, I., Kwon, H., Cho, E., Jeon, J., Yun, J., Lee, Y. C., Kim, D. H., & Ryu, J. H. (2019) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2019.076 · Cited by 19
Targeting Endothelin in Alzheimer’s Disease: A Promising Therapeutic Approach
Sharma, S., Behl, T., Kumar, A., Sehgal, A., Singh, S., Sharma, N., Bhatia, S., Al‐Harrasi, A., & BUNGAU, S. G. (2021) · BioMed Research International · doi:10.1155/2021/7396580 · Cited by 19
Pentkowski, N. S., Bouquin, S. J., Maestas-Olguin, C. R., Villasenor, Z. M., & Clark, B. J. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113661 · Cited by 18
Batool, S., Furqan, T., Mahmood, M. S. H., Tweedie, D., Kamal, M. A., & Greig, N. H. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00200 · Cited by 16
Self-citationExperimental approaches for altering the expression of Abeta‐degrading enzymes
Loeffler, D. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15762 · Cited by 18
Howell, E. H., & Cameron, S. J. (2016) · Cardiology Journal · doi:10.5603/cj.a2016.0063 · Cited by 16
Kelly, L., Sharp, M. M., Thomas, I., Brown, C., Schrag, M., Antunes, L. V., Solopova, E., Martínez‐González, J., Rodrı́guez, C., & Carare, R. O. (2023) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2023.100171 · Cited by 14
Amyloid beta peptide-degrading microbial enzymes and its implication in drug design
Dhanavade, M. J., & Sonawane, K. D. (2020) · 3 Biotech · doi:10.1007/s13205-020-02240-2 · Cited by 16
Yi, L., Luo, M., Wang, M., Dong, Z., & Du, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1288506 · Cited by 15
Herrera, M. L., Champarini, L. G., Oliveros, A. L., Bellini, M. J., & Hereñú, C. B. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00093 · Cited by 15
Chronic Traumatic Encephalopathy
Iacono, D., Shively, S. B., Edlow, B. L., & Perl, D. P. (2017) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2016.12.007 · Cited by 16
PhIP exposure in rodents produces neuropathology potentially relevant to Alzheimer’s disease
Syeda, T., Foguth, R. M., Llewellyn, E., & Cannon, J. R. (2020) · Toxicology · doi:10.1016/j.tox.2020.152436 · Cited by 15
Castro-Silva, E. S., Bello, M., Rosales‐Hernández, M. C., Correa‐Basurto, J., Rodríguez, M. H., Villalobos-Acosta, D. M. Á., Méndez‐Méndez, J. V., Estrada-Pérez, A. R., Murillo-Álvarez, J. I., & Muñoz‐Ochoa, M. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1729863 · Cited by 15
Exceptional in vivo catabolism of neurodegeneration-related aggregates
Datki, Z., Galik-Olah, Z., Hortobágyi, T., Mácsai, L., Zsuga, K., Fülöp, L., Bozsó, Z., Gálik, B., Ács, É., Földi, A., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0507-3 · Cited by 14
The Role of miR-20 in Health and Disease of the Central Nervous System
Arzhanov, I., Sintakova, K., & Romanyuk, N. (2022) · Cells · doi:10.3390/cells11091525 · Cited by 16
Li, N., Pang, Q., Zhang, Y., Lin, J., Li, H., Li, Z., Liu, Y., Fang, X., An, Y., Bai, H., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1103012 · Cited by 14
Molecular Pathways of Altered Brain Development in Fetuses Exposed to Hypoxia
Orzeł, A., Unrug-Bielawska, K., Filipecka‐Tyczka, D., Berbeka, K., Żeber‐Lubecka, N., Zielińska, M., & Kajdy, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210401 · Cited by 14
Gene therapy: an alternative to treat Alzheimer’s disease
Doshi, V., Joshi, G., Sharma, S., & Choudhary, D. K. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02873-z · Cited by 14
Cali, M. P., Pereira, L. M. B., Teodoro, M. D., Sellani, T. A., Rodrigues, E. G., & Carlos, R. M. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111314 · Cited by 14
Song, S., Wu, J., Cheng, Y., Ma, L., Liu, T., Liu, J., Liu, J., Sotor, J. Z., & Luan, P. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.101028 · Cited by 14
Huang, L., Liu, M., Li, Z., Li, B., Wang, J., & Zhang, K. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00865 · Cited by 13
Arber, C., Alatza, A., Leckey, C. A., Paterson, R. W., Zetterberg, H., & Wray, S. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15315 · Cited by 13
Park, S. E., Kim, H., Kwon, S. J., Kim, M.-J., Choi, S., Oh, S., Ryu, G. H., Jeon, H. B., Na, D. L., & Chang, J. W. (2021) · Stem Cells International · doi:10.1155/2021/6660186 · Cited by 13
Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure
Prenner, S. B., Shah, S. J., & Yancy, C. W. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0603-4 · Cited by 12
Krishnan, D., Menon, R. N., & Gopala, S. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-01023-w · Cited by 12
The Association between Neprilysin gene polymorphisms and Alzheimer’s disease in Tibetan population
Chen, S., Mima, D., Jin, H., Qu, D. C., Wang, F., Cai, J., Shi, L. S., Wang, H., Du, A., Tang, Y., et al. (2020) · Brain and Behavior · doi:10.1002/brb3.2002 · Cited by 12
Theerasri, A., Janpaijit, S., Tencomnao, T., & Prasansuklab, A. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1591 · Cited by 13
Potent therapeutic targets for treatment of Alzheimer's disease: Amyloid degrading enzymes
Choi, H. S., Kim, E., Choi, J. Y., Park, E., & Lee, H. J. (2021) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12390 · Cited by 11
Circular RNAs: New players involved in the regulation of cognition and cognitive diseases
Yu, X., Liu, H., Chang, N., Fu, W., Guo, Z., & Wang, Y. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1097878 · Cited by 11
Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts
Mousa, Y. M., Abdallah, I. M., Hwang, M., Martin, D. R., & Kaddoumi, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-60664-5 · Cited by 11
Sharma, H. S., Muresanu, D. F., Nozari, A., Lafuente, J. V., Buzoianu, A. D., Sahib, S., Tian, Z. R., Bryukhovetskiy, I., Manzhulo, I., Menon, P. K., et al. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.04.008 · Cited by 11
El-Baz, F. K., Jaleel, G. A. A., Hussein, R. A., & Saleh, D. O. (2021) · Toxicology Reports · doi:10.1016/j.toxrep.2021.11.021 · Cited by 11
Grover, P., Rohilla, S., Bhardwaj, M., Mehta, L., & Malhotra, A. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230406084315 · Cited by 11
Neprilysin Inhibition in the Time of Precision Medicine ∗
Feldman, A. M. (2016) · JACC Heart Failure · doi:10.1016/j.jchf.2016.02.016 · Cited by 11
Katsanos, S., Bistola, V., & Parissis, J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1153423 · Cited by 11
Paliwal, D., Mondal, R., & Thakur, A. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00364-y · Cited by 10
Kim, M., Park, M., Nam, G., Lee, M., Kang, J., Song, I., Choi, M., Jin, H. K., Bae, J., & Lim, M. H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00677 · Cited by 10
Metadata
- Authors
- Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K.
- Affiliations
- Medical University of South Carolina (US)
- Indiana University – Purdue University Indianapolis (US)
- Indiana University Bloomington (US)
- National Institutes of Health (US)
- The University of Texas Medical Branch at Galveston (US)
- ORCID
- Venue
- Current Alzheimer Research
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-01-03
- Volume
- 12
- Issue
- 1
- Pages
- 32-46
- ISSN
- 1567-2050 (ISSN-L)
- PMC
- PMC4820400
- OpenAlex
- W2136334732
- Cited by
- 331
- References
- 201
- Citations by year
- 2026: 9 · 2025: 26 · 2024: 14 · 2023: 30 · 2022: 34 · 2021: 44 · 2020: 45 · 2019: 45 · 2018: 31 · 2017: 22 · 2016: 20 · 2015: 10
- FWCI
- 20.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Alzheimer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health (5r21ag042804-02)
- National Institute on Aging (R21-AG042804, AG046200, R01AG022103, R21AG046200, AG042804)
- National Institute of General Medical Sciences (T32 GM08716-13, T32GM008716)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, Alzheimer's disease, amyloid-beta clearance, amyloid beta degradation, amyloid plaques, familial Alzheimer's disease, APP mutations, presenilin, gamma-secretase, BACE1, insulin-degrading enzyme, neprilysin, matrix metalloproteinases, APOE ε4, gamma-secretase inhibitors
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Humans, Models, Biological, Mutation, Signal Transduction, Amyloid beta-Peptides, Presenilin-1, Presenilin-2, Amyloid Precursor Protein Secretases, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
